The emerging role of microRNA-4487/6845-3p in Alzheimer's disease pathologies is induced by Aβ25-35 triggered in

Ling Hu1,2, Rong Zhang2, Qiong Yuan2

  • 1Department of Anesthesiology, Tianyou Hospital, Wuhan University of Science and Technology, Wuhan, 430064, China.

BMC Systems Biology
|December 15, 2018
PubMed
Abstract

Insights

Alzheimer's disease (AD) pathogenesis involves amyloid-beta (Aβ) and microRNAs (miRNAs). This study identifies two key miRNAs, hsa-miR-4487 and hsa-miR-6845-3p, involved in Aβ-induced cell apoptosis and synaptic dysfunction in AD.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Amyloid beta-peptide (Aβ) accumulation is central to Alzheimer's disease (AD) pathogenesis.
  • Aberrant regulation of neuron-enriched microRNAs (miRNAs) is observed in AD, but their specific role in Aβ accumulation remains unclear.
  • Understanding the molecular mechanisms of miRNA involvement in Aβ deposition is crucial for AD research.

Purpose of the Study:

  • To systematically identify miRNAs involved in Aβ deposition.
  • To elucidate the molecular mechanisms of target miRNAs in Aβ-induced cytotoxicity in SH-SY5Y cells.
  • To investigate the role of specific miRNAs in Aβ-mediated pathophysiology.

Main Methods:

  • Microarray analysis of miRNA expression in response to Aβ treatment.
  • Quantitative real-time PCR (qRT-PCR) to validate miRNA expression changes.
  • Assessment of cell apoptosis and axon damage in response to Aβ and miRNA modulation.

Main Results:

  • Microarray analysis identified 155 upregulated and 50 downregulated miRNAs.
  • hsa-miR-4487 was downregulated and hsa-miR-6845-3p was upregulated by Aβ25-35 in SH-SY5Y cells.
  • Increased hsa-miR-4487 inhibited cell apoptosis, while decreased hsa-miR-6845-3p attenuated Aβ25-35-mediated axon damage.

Conclusions:

  • Dysregulation of hsa-miR-4487 and hsa-miR-6845-3p contributes to AD pathogenesis via Aβ25-35, triggering cell apoptosis and synaptic dysfunction.
  • These findings offer insights into AD pathogenesis, potentially aiding clinical diagnosis and treatment.
  • Further validation studies will explore miRNA signatures as prognostication tools for AD clinical outcomes.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...